Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
Roe
M T
MT
Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Moliterno
D J
DJ
D000077284:Abciximab; D000208:Acute Disease; D000284:Administration, Oral; D000789:Angina, Unstable / Q000188:drug therapy; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001792:Blood Platelets / Q000502:physiology; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004562:Electrocardiography; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab